Contract manufacturing news in brief
pharmafile | September 11, 2009 | News story | Manufacturing and Production |Â Â Â
Newsflow in the contract manufacturing sector is picking up again as the summer draws to a close, with new agreements and contracts for Archimica and Chemic Labs, Aesica, Angel Biotechnology, Synco BioPartners, Cobra Biomanufacturing and Girindus.
Germany's Archimica is collaborating with Chemic Laboratories of the US in the areas of active pharmaceutical ingredient (API) research, development and production. The deal will see Archimica quickly scaling API production to commercial scale after Chemic develops and produces the first quantities, speeding the time it takes for products to be brought to market.
Aesica Pharmaceuticals has entered into a new multi-year supply agreement with Amdipharm in which it will provide manufacturing and packaging services for several of Amdipharm's leading products. Initially, the contracts cover Erythrocin (erythromycin), Hytrin (terazosin) and Loftyl (buflomedil) but they are expected to include additional products in the future. Manufacturing will be carried out at Aesica's finished dosage pharmaceutical production facility located in Kent, UK.
Angel Biotechnology will manufacture clinical-grade lots of a new formulation of ReNeuron's stem cell product CTX under a new contract signed between the two companies. The new version of the stem cell line will be used for preclinical and clinical testing, and makes it easier for the cells to be frozen for shipping and storage and thawed at the point of use. ReNeuron is developing CTX as a treatment for patients with peripheral artery disease and stroke.
Dutch contract manufacturer Synco BioPartners will manufacture a live biotherapeutic-based drug for cancer on behalf of an unnamed "emerging Japanese pharmaceutical company". The company said the contract is its first in Japan and will cover process development, transfer and scale-up in its Amsterdam-based manufacturing unit and GMP (good manufacturing practice) production of material for phase I trials, including fermentation, formulation and filling.
Cobra Biomanufacturing of the UK has forged an agreement with an unnamed European biotechnology company to provide development services for an adenovirus-based therapeutic product. The project will centre on the use of Cobra's proprietary virus purification platform, a fully-disposable system based on scalable chromatographic operations.
Girindus America will manufacture the API for Cellceutix Corp's Kevetrin product – in development as a treatment for several cancers – under a new contract signed by the two companies. Cellceutix said the deal was a major step forward to its goal of filing for approval to start clinical testing of the drug in the US. The firm said it would use the material for animal toxicology studies and phase I human trials.
a2a_linkname=”Pharmafocus”;a2a_linkurl=”http://www.pharmafocus.com”;a2a_num_services=6;a2a_prioritize=[”twitter”,”linkedin”,”facebook”,”delicious”,”friendfeed”,”stumbleupon”,”reddit”];
